Crossmark

The Effectiveness of Sorafenib over Other Targeted Agents in the Second-Line Treatment of Metastatic Renal Cell Carcinoma: a Meta-Analysis

Crossref DOI link: https://doi.org/10.1007/s12253-018-0516-3

Published Online: 2018-11-12

Published Print: 2019-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Huang, Hou-Feng

Fan, Xin-Rong

Ji, Zhi-Gang
License Information

Text and Data Mining valid from 2018-11-12
More Information

Article History

Received: 10 December 2017

Accepted: 21 October 2018

First Online: 12 November 2018

Compliance with Ethical Standards

:

: The authors declare they have no conflict of interest.